Direct Stent, no clinical utility in patients undergoing elective

 Original title: The Independent Value of a Direct Stenting Strategy on Early and Late Clinical Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention. Reference: Gabriel L. Sardi et al. Catheterization and Cardiovascular Interventions 81:949–956 (2013).

 

The use of direct stenting (DS) without pre-stenting dilation has proven to be a safe strategy, especially with the advances that have been achieved in the profile of the new generation devices. In theory, the incidence of peri-procedural myocardial injury and no-reflow phenomenon would be lower given the slightest chance of distal embolization and wall damage compared to pre systematic dilation. In this study, the decision regarding what strategy to use was at the discretion of the operator, so that propensity score was used to match the differences in baseline characteristics of both groups, which left 444 patients in each branch for the final analysis. 

The primary endpoint of the analysis was the extent of myocardial injury peri-procedural according to the elevation of CK-MB. The indicative variables of the use of resources such as procedure time, contrast volume and post dilatation balloons used were significantly higher in pre branch dilatation. The peri-procedural myocardial injury was virtually identical in both groups, (5.3% versus PD SD 5.4%, p = 0.91), as was the incidence of death, myocardial infarction, revascularization or a combination of all (MACE). 

Conclusion: 

In the context of elective angioplasty, a direct stenting strategy reduces procedure time and resource utilization but has no demonstrable clinical benefit at one year. 

Editorial comment: 

The mere fact of diminishing resources, and therefore costs, seems to be reason enough to use direct stenting. Perhaps the most important aspect is correctly judging the injury before starting and choosing a strategy according to the anatomical complexity. These results should not be extended to studying patients with acute coronary syndrome

SOLACI

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...